Matt Gorman is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. He is a member of the firm's employment litigation practice, which specializes in handling a variety of cases, including those involving race, sex, religion, age, national origin, harassment, and disability discrimination. In addition, Matt regularly counsels employers on hiring practices, employee and contractor classification, employment policies, employment contracts, terminations, and other issues that arise under federal, state, and local labor and employment laws.
Matt Gorman is a partner in the Boston office of Wilson Sonsini Goodrich & Rosati. He is a member of the firm's employment litigation practice, which specializes in handling a variety of cases, including those involving race, sex, religion, age, national origin, harassment, and disability discrimination. In addition, Matt regularly counsels employers on hiring practices, employee and contractor classification, employment policies, employment contracts, terminations, and other issues that arise under federal, state, and local labor and employment laws.
- J.D., New York University School of Law, 2010
- B.S., Industrial and Labor Relations, Cornell University, 2007
- State Bar of Massachusetts
- State Bar of New York
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
- J.D., New York University School of Law, 2010
- B.S., Industrial and Labor Relations, Cornell University, 2007
- State Bar of Massachusetts
- State Bar of New York
- U.S. District Court for the Eastern District of New York
- U.S. District Court for the Southern District of New York
Select Speaking Engagements
-
Panelist, “Navigating U.S. Business Disputes: A UK/European Company's Guide to Avoiding U.S. Litigation,” Wilson University, November 17, 2020
Select Speaking Engagements
-
Panelist, “Navigating U.S. Business Disputes: A UK/European Company's Guide to Avoiding U.S. Litigation,” Wilson University, November 17, 2020
The research-stage partnership entails a build-to-buy deal structure, including an upfront payment of $50 million from Merck KGaA, Darmstadt, Germany to fund Saturnus Bio’s research activities, securing a minority equity stake in the company, as well as additional success-based preclinical milestones, supporting the development of novel drug candidates for genetic cardiomyopathy patients. Merck KGaA, Darmstadt, Germany has exclusive rights to acquire Saturnus Bio for a pre-determined option payment, in addition to success-based earnouts.
The Wilson Sonsini team that advised Saturnus Bio on the transaction includes:
- Privacy Policy
- Terms of Use
- Accessibility